Effectiveness of Bladder Preservation Treatment For Patients with Superfcially Invasive Bladder Tumor(T2/T3a).
- Author:
Hyeon Seok LEE
1
;
Jae Mann SONG
Author Information
1. Department of Urology, Yonsei university, Wonju Medical College, Wonju, Korea.
- Publication Type:Original Article
- Keywords:
Bladder preservation;
Invasive bladder tumor;
M-VAC chemotherapy
- MeSH:
Appointments and Schedules;
Carcinoma, Transitional Cell;
Cystectomy;
Doxorubicin;
Drug Therapy;
Follow-Up Studies;
Humans;
Leukopenia;
Methotrexate;
Radiotherapy;
Urinary Bladder Neoplasms;
Urinary Bladder*;
Vinblastine
- From:Korean Journal of Urology
1995;36(6):601-608
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Radical cystectomy and/or radiotherapy represent the standard treatment for invasive bladder carcinoma. However these approaches are less than ideal since a substantial number of patients have progressive disease and die of metastatic cancer. Then recent treatment modality is trending toward chemotherapy. Therefore, we performed the aggressive transurethral resection of the bladder tumor (TURBt) followed by the combined chemotherapy of methotrexate, vinblastine, doxorubicin and cisplatin(RI-VAC) for conservative treatment of muscle invasive transitional cell carcinoma of the bladder. From July 1990 to March 1995, 41 patients with stage T2 to T4 were entered into the study. Of that patients, 26 completed 4 to 8 cycles of M-VAC and were followed, while 15 were excluded from the study because of incomplete chemotherapy or inadequate follow-up. Median follow-up was 30 months(4-56 months). Median age of the patients was 66 years(range 48 to 85 years). All patients had Karnofsky performance status(KPS) score between 70 and l00. There were 3 patients with clinical stage T2, 8 with T3a, 7 with T3b, 8 with T4. G-CSF(Granulocyte-Colony Stimulating Factor) was used for 19 patients with M-VAC induced leukopenia, thereby allowing the chemotherapy to be complete on schedule. Responses to therapy were evaluated according to standard accepted phase II response criteria. Overall clinical response (complete and partia1) was noted in 15 patients(58%), and no response in 11(42%). Of the patients with T2 and T3a, 9(82%) showed complete and partial response, and of them with T3b and T4, 6(40%) showed complete and partial response. Of 26 patients 21(81%) are alive now. These data suggest that survival was no better than expected following radical cystectomy or radiotherapy in short term follow-up, so far, however systemic M-VAC chemotherapy in combination with radical TURBt is probably expected to provide a high response rate and a better survival with the particular advantage of preserving normal bladder function in patients with superficially invasive bladder tumor(T2/T3a).
